Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)

NCT04892654 is registered in ClinicalTrials.gov with Chelsea and Westminster NHS Foundation Trust as lead sponsor.

NCT NCT04892654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (DORDOL)
Lead sponsor
Chelsea and Westminster NHS Foundation Trust
Phase
Phase 3
Overall status
Recruiting
Start date
August 17, 2022
Completion date
November 30, 2027
Enrollment
150 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection